Skip to content
ClinCalc Pro
Menu
Oral iron + vitamin C Pregnancy: §4.6 verbatim: 'Pregnancy Ferrous salts are recommended for use in pregnancy, and no contraindications to such are known. No special requirements are to be anticipated. Iron supplementation should not be routinely offered to all pregnant women in the absence of a diagnosis of iron deficiency anaemia. Breast-feeding Ferrous salts are recommended for use in lactation, and no contraindications to such are known. No special requirements are to be anticipated.' No pregnancy category letter is assigned in the UK SPC.

Ferrous sulfate with ascorbic acid

Brand names: Ferrograd C

Used in: Anaemia

This fixed combination of ferrous sulfate with ascorbic acid (vitamin C) is an oral preparation for treating and preventing iron-deficiency anaemia.

Adult dose

Dose: Oral iron supplementation — adults including the elderly: 1 tablet daily, taken before food. §4.2 quoted in full: 'Adults including the elderly 1 tablet daily. Take before food. Patients should be advised to swallow tablets whole.' Method of administration, §4.2 verbatim: 'The tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water. Tablets should be taken before meals or during meals, depending on gastrointestinal tolerance.' The SPC gives this one posology and does not split it by indication or by severity of deficiency.
Route: Oral. Swallow whole with water — §4.4 verbatim: 'Due to the risk of mouth ulcerations and tooth discolouration, tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water.'
Frequency: Once daily.
Max: 1 tablet daily. The SPC states no higher dose for any adult or elderly patient group and gives no dose escalation.
SCOPE — this record covers Ferrograd C prolonged-release tablets, the only brand this page names and the exact ferrous sulfate plus ascorbic acid combination in the page id. The UK SPC has now been found and is the source above; the homeopathic openFDA record is still present in the bundle and is still not used. ⚠️ WHAT IS STILL NOT SOURCED — the ELEMENTAL IRON content per tablet does not appear anywhere in the fetched sections. The two strengths appear only in the product title as '325 mg + 562.4 mg'; the fetched text nowhere states which strength belongs to which component and nowhere gives an elemental iron equivalent, so neither is asserted here. Any elemental-iron statement must be sourced separately. §4.1 (the licensed indication wording) was also not captured in this bundle, which is why the dose above is described by what the SPC actually says rather than by a quoted indication. FORMULATION HAZARDS, §4.4: 'The prolonged release tablet and its inert plastic matrix may cause a safety hazard in some elderly or other patients suffering from delayed intestinal transit.' And: 'Aspiration of iron sulfate tablets can cause necrosis of the bronchial mucosa… Elderly patients and patients who have difficulties swallowing should only be treated with iron sulfate tablets after a careful evaluation of the individual patient's risk of aspiration. Alternative formulations should be considered.' ADMINISTRATION SPACING, §4.5: oral iron should not be taken within one hour before or two hours after antacids, calcium supplements, tea, coffee, eggs, food or products containing bicarbonates, carbonate, oxalates or phosphates, milk or milk products, wholegrain breads and cereals or dietary fibre; tetracycline should be given three hours after or two hours before oral iron; oral iron should not be taken with or within two hours of an oral quinolone; and penicillamine should be given at least two hours apart.

Paediatric dose

Route: Oral
Frequency: Once daily — 12 years and over only
Max: 1 tablet daily
§4.2 'Children' quoted in full: 'Not recommended for children under 12 years. Above this age, as for adults.' So from 12 years the dose is the adult dose — 1 tablet daily, taken before food and swallowed whole — and under 12 years this product is not recommended at all. The dose is NOT weight-based, so dosePerKg is deliberately null and the weight calculator is left unset; no mg/kg figure appears anywhere in this SPC. ⚠️ §4.4 verbatim: 'Ferrograd C tablets should be kept out of children's reach. Acute iron poisoning occurs rarely in adults, however it could happen if children swallow this medication.' The label carries the warning 'Important warning: Contains iron. Keep out of the reach and sight of children, as overdose may be fatal'. Iron dosing for a child under 12 must be prescribed against a children's formulary using an age-appropriate preparation.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • §4.3 verbatim: 'Intestinal diverticular disease or any intestinal obstruction.'
  • §4.3 verbatim: 'Iron preparations are contra-indicated in patients with haemochromatosis and haemosiderosis.'
  • §4.3 verbatim: 'Iron is contra-indicated in patients receiving repeated blood transfusions.'
  • §4.3 verbatim: 'Oral iron preparations are contra-indicated when used concomitantly with parenteral iron therapy.'

Side effects

  • §4.8 verbatim: 'Side-effects reported are similar to those associated with conventional oral iron preparations, i.e. nausea, vomiting, abdominal pain or discomfort, blackening of stools, diarrhoea and/or constipation, but the incidence of side-effects is less owing to the prolonged release nature of the formulation.'
  • Frequency not known, §4.8 gastrointestinal disorders: nausea; vomiting; abdominal pain or discomfort; blackening of stools; diarrhoea and/or constipation.
  • Frequency not known, §4.8: mouth ulceration 'in the context of incorrect administration, when the tablets are chewed, sucked or kept in mouth'.
  • §4.8: 'Elderly patients and patients with deglutition disorders may also be at risk of oesophageal lesions or of bronchial necrosis, in case of false route'.
  • §4.8: bronchial stenosis (see §4.4 — aspiration of iron sulfate tablets can cause necrosis of the bronchial mucosa, presenting as coughing, haemoptysis, bronchostenosis and/or pulmonary infection, potentially days to months after the aspiration).
  • §4.8: 'Isolated cases of allergic reaction have been reported ranging from rash to anaphylaxis.'
  • §4.8, ascorbic acid component: 'Ascorbic acid is usually well tolerated. However, large doses are reported to cause diarrhoea and other gastrointestinal disturbances and are associated with the formation of renal calcium oxalate calculi.'

Monitoring

  • §4.4 verbatim: 'Iron preparations colour the faeces black, which may interfere with tests used for detection of occult blood in the stools. The guaiac test occasionally yields false positive tests for blood.' Interpret faecal occult blood results with this in mind.
  • §4.4: before prescribing to an elderly patient or anyone with swallowing difficulty, carry out 'a careful evaluation of the individual patient's risk of aspiration' and consider an alternative formulation. 'Patients should seek medical attention in case of suspected aspiration.'
  • §4.4: use with caution where intestinal transit is delayed — the prolonged-release tablet's inert plastic matrix 'may cause a safety hazard' in such patients.
  • §4.5: review co-prescribed tetracyclines, quinolones, penicillamine, antacids, calcium, magnesium trisilicate, trientine and zinc salts for absorption interference in both directions, and separate the doses as the SPC specifies.

Clinical monograph

How it works

Ferrous sulfate provides absorbable iron[II] for haemoglobin synthesis, while ascorbic acid acts as a reducing agent that helps keep iron in the ferrous state and may modestly enhance its intestinal absorption.

Prescribing in practice

  • As with all iron products, accidental overdose is dangerous and potentially fatal in children, so secure storage out of reach is the priority safety point.
  • The same absorption interactions apply as for plain ferrous sulfate, requiring separation from tea, antacids, calcium and chelated drugs such as quinolones, tetracyclines and levothyroxine.
  • The added ascorbic acid offers only a modest absorption benefit and does not reduce the gastrointestinal side effects typical of oral iron.

Monitoring

Reassess haemoglobin and iron indices after several weeks, continuing treatment beyond normalisation to replenish stores.

Counselling the patient

  • Black stools are normal with this iron-containing product.
  • Keep away from children because of the risk of serious overdose.
  • Avoid taking with tea, milk or indigestion remedies at the same time.

Evidence & guidelines

Oral ferrous salts are first-line for iron-deficiency anaemia per NICE; the contribution of added vitamin C to absorption in practice is generally regarded as small.

Reference: Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.